ZyVersa Therapeutics (ZVSA) Life Sciences Investor Forum summary

Conference overview

• Presentation focused on innovative therapies targeting kidney disease and inflammation, with roots in University of Miami research.

• Two main programs: IC100 (inflammation/obesity) nearing clinical stage, and VAR-200 (kidney disease) entering phase II trials.

• Company has secured strong patent positions and leverages academic partnerships for research and development.

• Emphasis on combination therapies for obesity-related comorbidities, aligning with industry trends.

• Recent $4 million capital raise supports operations through Q1 2025, with ongoing plans for additional funding.

Industry trends and scientific focus

• Obesity and metabolic diseases are shifting toward combination therapies, especially with GLP-1 drugs.

• Inflammation, particularly via inflammasomes, is recognized as a key driver of obesity-related comorbidities.

• Major pharma companies are investing in inflammasome inhibitors to address comorbidities like CV disease and diabetes.

• IC100 targets multiple inflammasomes and ASC speck, aiming to block inflammation at both acute and chronic stages.

• Preclinical DIO models are underway to test IC100 as monotherapy and in combination with GLP-1s.

Pipeline and clinical milestones

• VAR-200 for diabetic kidney disease is ready for phase II, with first patient dosing expected in Q1 2025.

• Interim readouts for VAR-200 anticipated by Q2 2025.

• IC100 preclinical data to be reported in the next 3-6 months, focusing on metabolic, cardiovascular, and kidney disease intersections.

• Collaboration with Michael J. Fox Foundation on obesity and CNS inflammation research.

• Manufacturing and animal studies are conducted via partnerships with industry leaders and academic labs.